カテゴリ： 世界, 医療/バイオ, QYResearch

ジェネリック抗がん注射剤の世界市場2023年：ベバシズマ、リツキシマブ、ハーセプチン、パクリタキセル、その他

■ 英語タイトル：Global Generic Anti-cancer Injectables Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8770）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8770
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：90
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ジェネリック抗がん注射剤の世界市場2023年：ベバシズマ、リツキシマブ、ハーセプチン、パクリタキセル、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料はジェネリック抗がん注射剤のグローバル市場について調査・分析し、世界のジェネリック抗がん注射剤市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ベバシズマ、リツキシマブ、ハーセプチン、パクリタキセル、その他）、用途別セグメント分析（病院、小売）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Teva、Viatris、Biocon、Amgen、Sandoz (Novartis)、Pfizer、Qilu Pharmaceutical、Jiangsu Hansoh、CTTQ、Jiangsu Hengrui、CSPC、Innovent Biologicsなどが含まれています。ジェネリック抗がん注射剤のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、ジェネリック抗がん注射剤市場規模を算出する際に考慮しました。

・ジェネリック抗がん注射剤市場の概要
- ジェネリック抗がん注射剤の種類別セグメント
- 世界のジェネリック抗がん注射剤市場規模：タイプ別分析（ベバシズマ、リツキシマブ、ハーセプチン、パクリタキセル、その他）
- ジェネリック抗がん注射剤の用途別セグメント
- 世界のジェネリック抗がん注射剤市場規模：用途別分析（病院、小売）
- 世界のジェネリック抗がん注射剤市場規模予測（2018年-2029年）

・ジェネリック抗がん注射剤市場の成長トレンド
- ジェネリック抗がん注射剤の地域別市場規模（2018年-2029年）
- ジェネリック抗がん注射剤市場ダイナミクス
- ジェネリック抗がん注射剤の業界動向
- ジェネリック抗がん注射剤市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：ベバシズマ、リツキシマブ、ハーセプチン、パクリタキセル、その他
- 世界のジェネリック抗がん注射剤のタイプ別市場規模（2018年-2023年）
- 世界のジェネリック抗がん注射剤のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、小売
- 世界のジェネリック抗がん注射剤の用途別市場規模（2018年-2023年）
- 世界のジェネリック抗がん注射剤の用途別市場規模（2024年-2029年）

・ジェネリック抗がん注射剤の地域別市場規模
- 北米のジェネリック抗がん注射剤市場規模（2018年-2029年）
- 米国のジェネリック抗がん注射剤市場規模（2018年-2029年）
- ヨーロッパのジェネリック抗がん注射剤市場規模（2018年-2029年）
- アジア太平洋のジェネリック抗がん注射剤市場規模（2018年-2029年）
- 中国のジェネリック抗がん注射剤市場規模（2018年-2029年）
- 日本のジェネリック抗がん注射剤市場規模（2018年-2029年）
- 韓国のジェネリック抗がん注射剤市場規模（2018年-2029年）
- インドのジェネリック抗がん注射剤市場規模（2018年-2029年）
- オーストラリアのジェネリック抗がん注射剤市場規模（2018年-2029年）
- 中南米のジェネリック抗がん注射剤市場規模（2018年-2029年）
- 中東・アフリカのジェネリック抗がん注射剤市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Teva、Viatris、Biocon、Amgen、Sandoz (Novartis)、Pfizer、Qilu Pharmaceutical、Jiangsu Hansoh、CTTQ、Jiangsu Hengrui、CSPC、Innovent Biologics

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Generic Anti-cancer Injectables market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Generic Anti-cancer Injectables is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Generic Anti-cancer Injectables is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Generic Anti-cancer Injectables in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Generic Anti-cancer Injectables include Teva, Viatris, Biocon, Amgen, Sandoz (Novartis), Pfizer, Qilu Pharmaceutical, Jiangsu Hansoh and CTTQ, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic Anti-cancer Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Anti-cancer Injectables.
The Generic Anti-cancer Injectables market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Generic Anti-cancer Injectables market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic Anti-cancer Injectables companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics
Segment by Type
Bevacizuma
Rituximab
Herceptin
Paclitaxel
Others
Segment by Application
Hospital
Retail
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Generic Anti-cancer Injectables companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Bevacizuma
1.2.3 Rituximab
1.2.4 Herceptin
1.2.5 Paclitaxel
1.2.6 Others
1.3 Market by Application
1.3.1 Global Generic Anti-cancer Injectables Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Generic Anti-cancer Injectables Market Perspective (2018-2029)
2.2 Generic Anti-cancer Injectables Growth Trends by Region
2.2.1 Global Generic Anti-cancer Injectables Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Generic Anti-cancer Injectables Historic Market Size by Region (2018-2023)
2.2.3 Generic Anti-cancer Injectables Forecasted Market Size by Region (2024-2029)
2.3 Generic Anti-cancer Injectables Market Dynamics
2.3.1 Generic Anti-cancer Injectables Industry Trends
2.3.2 Generic Anti-cancer Injectables Market Drivers
2.3.3 Generic Anti-cancer Injectables Market Challenges
2.3.4 Generic Anti-cancer Injectables Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Generic Anti-cancer Injectables Players by Revenue
3.1.1 Global Top Generic Anti-cancer Injectables Players by Revenue (2018-2023)
3.1.2 Global Generic Anti-cancer Injectables Revenue Market Share by Players (2018-2023)
3.2 Global Generic Anti-cancer Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Generic Anti-cancer Injectables Revenue
3.4 Global Generic Anti-cancer Injectables Market Concentration Ratio
3.4.1 Global Generic Anti-cancer Injectables Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic Anti-cancer Injectables Revenue in 2022
3.5 Generic Anti-cancer Injectables Key Players Head office and Area Served
3.6 Key Players Generic Anti-cancer Injectables Product Solution and Service
3.7 Date of Enter into Generic Anti-cancer Injectables Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic Anti-cancer Injectables Breakdown Data by Type
4.1 Global Generic Anti-cancer Injectables Historic Market Size by Type (2018-2023)
4.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2024-2029)
5 Generic Anti-cancer Injectables Breakdown Data by Application
5.1 Global Generic Anti-cancer Injectables Historic Market Size by Application (2018-2023)
5.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Generic Anti-cancer Injectables Market Size (2018-2029)
6.2 North America Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Generic Anti-cancer Injectables Market Size by Country (2018-2023)
6.4 North America Generic Anti-cancer Injectables Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Generic Anti-cancer Injectables Market Size (2018-2029)
7.2 Europe Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Generic Anti-cancer Injectables Market Size by Country (2018-2023)
7.4 Europe Generic Anti-cancer Injectables Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Generic Anti-cancer Injectables Market Size (2018-2029)
8.2 Asia-Pacific Generic Anti-cancer Injectables Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2018-2023)
8.4 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Generic Anti-cancer Injectables Market Size (2018-2029)
9.2 Latin America Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Generic Anti-cancer Injectables Market Size by Country (2018-2023)
9.4 Latin America Generic Anti-cancer Injectables Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Generic Anti-cancer Injectables Market Size (2018-2029)
10.2 Middle East & Africa Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2018-2023)
10.4 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Generic Anti-cancer Injectables Introduction
11.1.4 Teva Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.1.5 Teva Recent Development
11.2 Viatris
11.2.1 Viatris Company Detail
11.2.2 Viatris Business Overview
11.2.3 Viatris Generic Anti-cancer Injectables Introduction
11.2.4 Viatris Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.2.5 Viatris Recent Development
11.3 Biocon
11.3.1 Biocon Company Detail
11.3.2 Biocon Business Overview
11.3.3 Biocon Generic Anti-cancer Injectables Introduction
11.3.4 Biocon Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.3.5 Biocon Recent Development
11.4 Amgen
11.4.1 Amgen Company Detail
11.4.2 Amgen Business Overview
11.4.3 Amgen Generic Anti-cancer Injectables Introduction
11.4.4 Amgen Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.4.5 Amgen Recent Development
11.5 Sandoz (Novartis)
11.5.1 Sandoz (Novartis) Company Detail
11.5.2 Sandoz (Novartis) Business Overview
11.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Introduction
11.5.4 Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.5.5 Sandoz (Novartis) Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Generic Anti-cancer Injectables Introduction
11.6.4 Pfizer Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Qilu Pharmaceutical
11.7.1 Qilu Pharmaceutical Company Detail
11.7.2 Qilu Pharmaceutical Business Overview
11.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Introduction
11.7.4 Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.7.5 Qilu Pharmaceutical Recent Development
11.8 Jiangsu Hansoh
11.8.1 Jiangsu Hansoh Company Detail
11.8.2 Jiangsu Hansoh Business Overview
11.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Introduction
11.8.4 Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.8.5 Jiangsu Hansoh Recent Development
11.9 CTTQ
11.9.1 CTTQ Company Detail
11.9.2 CTTQ Business Overview
11.9.3 CTTQ Generic Anti-cancer Injectables Introduction
11.9.4 CTTQ Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.9.5 CTTQ Recent Development
11.10 Jiangsu Hengrui
11.10.1 Jiangsu Hengrui Company Detail
11.10.2 Jiangsu Hengrui Business Overview
11.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Introduction
11.10.4 Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.10.5 Jiangsu Hengrui Recent Development
11.11 CSPC
11.11.1 CSPC Company Detail
11.11.2 CSPC Business Overview
11.11.3 CSPC Generic Anti-cancer Injectables Introduction
11.11.4 CSPC Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.11.5 CSPC Recent Development
11.12 Innovent Biologics
11.12.1 Innovent Biologics Company Detail
11.12.2 Innovent Biologics Business Overview
11.12.3 Innovent Biologics Generic Anti-cancer Injectables Introduction
11.12.4 Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.12.5 Innovent Biologics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Generic Anti-cancer Injectables Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Bevacizuma
Table 3. Key Players of Rituximab
Table 4. Key Players of Herceptin
Table 5. Key Players of Paclitaxel
Table 6. Key Players of Others
Table 7. Global Generic Anti-cancer Injectables Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Generic Anti-cancer Injectables Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Generic Anti-cancer Injectables Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Generic Anti-cancer Injectables Market Share by Region (2018-2023)
Table 11. Global Generic Anti-cancer Injectables Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Generic Anti-cancer Injectables Market Share by Region (2024-2029)
Table 13. Generic Anti-cancer Injectables Market Trends
Table 14. Generic Anti-cancer Injectables Market Drivers
Table 15. Generic Anti-cancer Injectables Market Challenges
Table 16. Generic Anti-cancer Injectables Market Restraints
Table 17. Global Generic Anti-cancer Injectables Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Generic Anti-cancer Injectables Market Share by Players (2018-2023)
Table 19. Global Top Generic Anti-cancer Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2022)
Table 20. Ranking of Global Top Generic Anti-cancer Injectables Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Generic Anti-cancer Injectables Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Generic Anti-cancer Injectables Product Solution and Service
Table 24. Date of Enter into Generic Anti-cancer Injectables Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Generic Anti-cancer Injectables Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2018-2023)
Table 28. Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2024-2029)
Table 30. Global Generic Anti-cancer Injectables Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Generic Anti-cancer Injectables Revenue Market Share by Application (2018-2023)
Table 32. Global Generic Anti-cancer Injectables Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Generic Anti-cancer Injectables Revenue Market Share by Application (2024-2029)
Table 34. North America Generic Anti-cancer Injectables Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America Generic Anti-cancer Injectables Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Generic Anti-cancer Injectables Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe Generic Anti-cancer Injectables Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific Generic Anti-cancer Injectables Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America Generic Anti-cancer Injectables Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America Generic Anti-cancer Injectables Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa Generic Anti-cancer Injectables Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US$ Million)
Table 49. Teva Company Detail
Table 50. Teva Business Overview
Table 51. Teva Generic Anti-cancer Injectables Product
Table 52. Teva Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 53. Teva Recent Development
Table 54. Viatris Company Detail
Table 55. Viatris Business Overview
Table 56. Viatris Generic Anti-cancer Injectables Product
Table 57. Viatris Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 58. Viatris Recent Development
Table 59. Biocon Company Detail
Table 60. Biocon Business Overview
Table 61. Biocon Generic Anti-cancer Injectables Product
Table 62. Biocon Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 63. Biocon Recent Development
Table 64. Amgen Company Detail
Table 65. Amgen Business Overview
Table 66. Amgen Generic Anti-cancer Injectables Product
Table 67. Amgen Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 68. Amgen Recent Development
Table 69. Sandoz (Novartis) Company Detail
Table 70. Sandoz (Novartis) Business Overview
Table 71. Sandoz (Novartis) Generic Anti-cancer Injectables Product
Table 72. Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 73. Sandoz (Novartis) Recent Development
Table 74. Pfizer Company Detail
Table 75. Pfizer Business Overview
Table 76. Pfizer Generic Anti-cancer Injectables Product
Table 77. Pfizer Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 78. Pfizer Recent Development
Table 79. Qilu Pharmaceutical Company Detail
Table 80. Qilu Pharmaceutical Business Overview
Table 81. Qilu Pharmaceutical Generic Anti-cancer Injectables Product
Table 82. Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 83. Qilu Pharmaceutical Recent Development
Table 84. Jiangsu Hansoh Company Detail
Table 85. Jiangsu Hansoh Business Overview
Table 86. Jiangsu Hansoh Generic Anti-cancer Injectables Product
Table 87. Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 88. Jiangsu Hansoh Recent Development
Table 89. CTTQ Company Detail
Table 90. CTTQ Business Overview
Table 91. CTTQ Generic Anti-cancer Injectables Product
Table 92. CTTQ Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 93. CTTQ Recent Development
Table 94. Jiangsu Hengrui Company Detail
Table 95. Jiangsu Hengrui Business Overview
Table 96. Jiangsu Hengrui Generic Anti-cancer Injectables Product
Table 97. Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 98. Jiangsu Hengrui Recent Development
Table 99. CSPC Company Detail
Table 100. CSPC Business Overview
Table 101. CSPC Generic Anti-cancer Injectables Product
Table 102. CSPC Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 103. CSPC Recent Development
Table 104. Innovent Biologics Company Detail
Table 105. Innovent Biologics Business Overview
Table 106. Innovent Biologics Generic Anti-cancer Injectables Product
Table 107. Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US$ Million)
Table 108. Innovent Biologics Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Generic Anti-cancer Injectables Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Generic Anti-cancer Injectables Market Share by Type: 2022 VS 2029
Figure 3. Bevacizuma Features
Figure 4. Rituximab Features
Figure 5. Herceptin Features
Figure 6. Paclitaxel Features
Figure 7. Others Features
Figure 8. Global Generic Anti-cancer Injectables Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Generic Anti-cancer Injectables Market Share by Application: 2022 VS 2029
Figure 10. Hospital Case Studies
Figure 11. Retail Case Studies
Figure 12. Generic Anti-cancer Injectables Report Years Considered
Figure 13. Global Generic Anti-cancer Injectables Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Generic Anti-cancer Injectables Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Generic Anti-cancer Injectables Market Share by Region: 2022 VS 2029
Figure 16. Global Generic Anti-cancer Injectables Market Share by Players in 2022
Figure 17. Global Top Generic Anti-cancer Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Generic Anti-cancer Injectables Revenue in 2022
Figure 19. North America Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Generic Anti-cancer Injectables Market Share by Country (2018-2029)
Figure 21. United States Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Generic Anti-cancer Injectables Market Share by Country (2018-2029)
Figure 25. Germany Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. France Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. U.K. Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Italy Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Russia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Nordic Countries Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Generic Anti-cancer Injectables Market Share by Region (2018-2029)
Figure 33. China Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Japan Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. South Korea Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Southeast Asia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. India Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Australia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Generic Anti-cancer Injectables Market Share by Country (2018-2029)
Figure 41. Mexico Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Brazil Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Generic Anti-cancer Injectables Market Share by Country (2018-2029)
Figure 45. Turkey Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Saudi Arabia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Teva Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 48. Viatris Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 49. Biocon Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 50. Amgen Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 51. Sandoz (Novartis) Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 52. Pfizer Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 53. Qilu Pharmaceutical Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 54. Jiangsu Hansoh Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 55. CTTQ Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 56. Jiangsu Hengrui Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 57. CSPC Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 58. Innovent Biologics Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 大腸がん分子診断学の世界市場2023年：ポリメラーゼ連鎖反応 PCR、分子ハイブリダイゼーション、バイオチップ、その他
  • ポイントオブケア（POC）がんスクリーニングの世界市場2023年：遺伝子検査、画像検査、その他
  • 医薬品用滅菌注射剤の世界市場2023年：高分子医薬品滅菌注射剤、低分子医薬品滅菌注射剤
  • 非筋層浸潤性膀胱がん治療薬の世界市場2023年：膀胱内化学療法、膀胱内免疫療法
  • 家禽/家畜抗感染症薬の世界市場2023年：外用、内用
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8770 )"ジェネリック抗がん注射剤の世界市場2023年：ベバシズマ、リツキシマブ、ハーセプチン、パクリタキセル、その他" (英文：Global Generic Anti-cancer Injectables Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。